A citation-based method for searching scientific literature

Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin M Valdes, Elizabeth H Z Thompson, Hervé Bachelez. Lancet 2018
Times Cited: 290



Alan Menter, Bruce E Strober, Daniel H Kaplan, Dario Kivelevitch, Elizabeth Farley Prater, Benjamin Stoff, April W Armstrong, Cody Connor, Kelly M Cordoro, Dawn M R Davis, Boni E Elewski, Joel M Gelfand, Kenneth B Gordon, Alice B Gottlieb, Arthur Kavanaugh, Matthew Kiselica, Neil J Korman, Daniela Kroshinsky, Mark Lebwohl, Craig L Leonardi, Jason Lichten, Henry W Lim, Nehal N Mehta, Amy S Paller, Sylvia L Parra, Arun L Pathy, Reena N Rupani, Michael Siegel, Emily B Wong, Jashin J Wu, Vidhya Hariharan, Craig A Elmets. J Am Acad Dermatol 2019
Times Cited: 303




List of shared articles



Times cited


PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines.
Isabel Belinchón Romero, Esteban Dauden, Carlos Ferrándiz Foraster, Álvaro González-Cantero, Jose Manuel Carrascosa Carrillo. J Dermatolog Treat 2022
3

Saudi consensus statement on biologic treatment of chronic plaque psoriasis (2020).
Mohammad Ibrahim Ahmad Fatani, Issam Ribhi Ahmad Hamadah, Mohammed Abdulaziz Alajlan, Yousef Binamer, Aymen Hamed Salem Alharbi, Amaal Farhan Salman Alruwaili, Maha Abdulrahman Abdulateef Aldayel, Khalidah Ahmed Owdetallah Alenzi, Sultan Mohammed Mubarki, Amr Mohammad Khardaly,[...]. J Dermatolog Treat 2022
1

T-cell subsets in the skin and their role in inflammatory skin disorders.
Inge Kortekaas Krohn, Joeri L Aerts, Karine Breckpot, Cleo Goyvaerts, Edward Knol, Femke Van Wijk, Jan Gutermuth. Allergy 2022
5

Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis.
April W Armstrong, Ahmed M Soliman, Keith A Betts, Yan Wang, Yawen Gao, Vassilis Stakias, Luis Puig. Dermatol Ther (Heidelb) 2022
6


Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
Jeffrey J Crowley, Richard G Langley, Kenneth B Gordon, Andreas Pinter, Laura K Ferris, Simone Rubant, Huzefa Photowala, Zhenyi Xue, Tianshuang Wu, Tianyu Zhan,[...]. Dermatol Ther (Heidelb) 2022
2

Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease.
Cassandra Marie Townsend, Fiona Lovegrove, Reena Khanna, Aze Suzanne Wilson. Aliment Pharmacol Ther 2022
0



Endothelial Dysfunction in Psoriasis: An Updated Review.
Panagiota Anyfanti, Anastasia Margouta, Kyriakos Goulas, Maria Gavriilaki, Elizabeth Lazaridou, Aikaterini Patsatsi, Eugenia Gkaliagkousi. Front Med (Lausanne) 2022
0

Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.
April Armstrong, Kyle Fahrbach, Craig Leonardi, Matthias Augustin, Binod Neupane, Paulina Kazmierska, Marissa Betts, Andreas Freitag, Sandeep Kiri, Vanessa Taieb,[...]. Dermatol Ther (Heidelb) 2022
2

Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis.
Christine P Lin, Joseph F Merola, Elizabeth B Wallace. Curr Opin Pharmacol 2022
0

Anti-IL 23 biologics for the treatment of plaque psoriasis.
Alan Vu, Caden Ulschmid, Kenneth B Gordon. Expert Opin Biol Ther 2022
0